Functional characterization of a fluorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models

International Journal of Gynecological Cancer

Volumn 21, Issue 3, 2011, Pages 457-465

  Ingersoll, Susan Blaydes ^a,b   Ahmad, Sarfraz ^a,b,c   Stoltzfus, Gregory P ^a   Patel, Sheylan ^a   Radi, Michael J ^a   Finkler, Neil J ^a,b,c   Edwards, John R ^c,d   Holloway, Robert W ^a,b,c  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

^d Lifeforce Cryobanks   (United States)

Author keywords

Cellular therapy; Cytokines; Cytoxicity; Functional characterization; Mouse model; Ovarian cancer

Indexed keywords

ALPHA2B INTERFERON; CYSTEINE RICH PROTEIN 61; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MACROGOL; RED FLUORESCENT PROTEIN; UVOMORULIN; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE INCREASE; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INCIDENCE; LOW DRUG DOSE; MOUSE; NONHUMAN; NORMAL HUMAN; NUDE MOUSE; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; XENOGRAFT; ANIMAL; CYTOLOGY; METABOLISM; MONONUCLEAR CELL; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, NUDE; OVARIAN NEOPLASMS;

EID: 80051647341     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820f4ef0     Document Type: Article

References (25)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
2. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43. (Pubitemid 43048949)
3. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19: 1001-1007. (Pubitemid 32176274)
4. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol. 2003;21:2451-2453. (Pubitemid 46894005)
5. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158-166.
6. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl JMed. 2003;348:203-213. (Pubitemid 36077915)
7. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897. (Pubitemid 17041979)
8. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993;11:661-670. (Pubitemid 23105674)
9. Tourani JM, Pfister C, Tubiana N, et al. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, non-randomized study with sequential analysis design - the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol. 2003;21:3987-3994. (Pubitemid 46606213)
10. Ingersoll SB, Patel S, Caballero L, et al. Synergistic cytotoxicity of interferon alpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy. Gynecol Oncol. 2009;112:192-198.
11. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115: 61-69.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63. (Pubitemid 14203433)
13. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res. 2001;21:1103-1115. (Pubitemid 34121056)
14. Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis. 2006;23:65-74. (Pubitemid 44576780)
15. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet. 2004;363:62-64. (Pubitemid 38076928)
16. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int. 2003;3:1-15.
17. Tsai MS, Hornby AE, Lakins J, et al. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 2000;60:5603-5607.
18. Xie D, Miller CW, O'Kelly J, et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem. 2001;276:14187-14194.
19. Xie D, Nakachi K, Wang H, et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001;61:8917-8923. (Pubitemid 34013909)
20. Gery S, Xie D, Yin D, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 2005;11:7243-7254. (Pubitemid 41507681)
21. Tedjarati S, Baker CH, Apte S, et al. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res. 2002;8:2413-2422. (Pubitemid 34753617)
22. Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161:290-297.
23. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327-333. (Pubitemid 34461490)
24. Kalinski P, Mailliard RB, Giermasz A, et al. Natural killerYdendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005;5:1303-1315. (Pubitemid 41503042)
25. Mailliard RB, Son YI, Redlinger R, et al. Dendritic cells mediate NK cell help for TH1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003;171:2366-2373. (Pubitemid 37025543)